- Home
- PHVS vs PFLT Comparison
PHVS vs PFLT Comparison
Compare PHVS & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- PFLT
- Stock Information
- Founded
- PHVS 2015
- PFLT 2010
- Country
- PHVS Switzerland
- PFLT United States
- Employees
- PHVS N/A
- PFLT N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- PHVS Health Care
- PFLT Finance
- Exchange
- PHVS Nasdaq
- PFLT Nasdaq
- Market Cap
- PHVS 909.5M
- PFLT 1.0B
- IPO Year
- PHVS 2021
- PFLT N/A
- Fundamental
- Price
- PHVS $17.99
- PFLT $10.27
- Analyst Decision
- PHVS Buy
- PFLT Buy
- Analyst Count
- PHVS 6
- PFLT 5
- Target Price
- PHVS $37.17
- PFLT $11.20
- AVG Volume (30 Days)
- PHVS 62.5K
- PFLT 801.8K
- Earning Date
- PHVS 08-13-2025
- PFLT 08-06-2025
- Dividend Yield
- PHVS N/A
- PFLT 11.99%
- EPS Growth
- PHVS N/A
- PFLT N/A
- EPS
- PHVS N/A
- PFLT 0.86
- Revenue
- PHVS N/A
- PFLT $232,975,000.00
- Revenue This Year
- PHVS N/A
- PFLT $45.52
- Revenue Next Year
- PHVS N/A
- PFLT $8.87
- P/E Ratio
- PHVS N/A
- PFLT $11.90
- Revenue Growth
- PHVS N/A
- PFLT 49.56
- 52 Week Low
- PHVS $11.51
- PFLT $8.82
- 52 Week High
- PHVS $25.50
- PFLT $12.02
- Technical
- Relative Strength Index (RSI)
- PHVS 58.65
- PFLT 55.27
- Support Level
- PHVS $16.00
- PFLT $10.11
- Resistance Level
- PHVS $17.53
- PFLT $10.60
- Average True Range (ATR)
- PHVS 1.14
- PFLT 0.15
- MACD
- PHVS 0.01
- PFLT -0.00
- Stochastic Oscillator
- PHVS 59.77
- PFLT 62.26
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.